Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Archives of Psychiatry and Clinical Neuroscience
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 5/2013

01.08.2013 | Original Paper

No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression

verfasst von: Richard Musil, Peter Zill, Florian Seemüller, Brigitta Bondy, Michael Obermeier, Ilja Spellmann, Wolfram Bender, Mazda Adli, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Wolfgang Maier, Marcella Rietschel, Dan Rujescu, Rebecca Schennach, Hans-Jürgen Möller, Michael Riedel

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The role of the brain-derived neurotrophic factor (BDNF) in the pathophysiology of major depressive disorder (MDD) remains to be elucidated. Recent post hoc analyses indicated a potential association of three polymorphisms in the BDNF gene with worse treatment outcome in patients with the subtype of melancholic depression. We aimed at replicating these findings in a German naturalistic multicenter follow-up. Three polymorphisms in the BDNF gene (rs7103411, rs6265 (Val66Met) and rs7124442) were genotyped in 324 patients with MDD and 470 healthy controls. We applied univariate tests and logistic regression models stratifying for depression subtype and gender. The three polymorphisms were not associated with MDD as diagnosis. Further, no associations were found in univariate tests. With logistic regression, we only found a tendency towards an association of the rs6265 (Val66Met) polymorphism with overall response to treatment (response rates: GG (val/val) < GA (val/met) < AA (met/met); p = 0.0129) and some gender differences for the rs6265 (Val66Met) and rs7103411 polymorphisms. Treatment outcome stratified for subtypes of depression did not differ significantly between the investigated polymorphisms or using haplotype analyses. However, results showed a tendency towards significance. At this stage, we cannot support an influence of these three polymorphisms. Further studies in larger patient samples to increase sample sizes of subgroups are warranted.
Literatur
1.
2.
Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597–606PubMedCrossRef
3.
Scharinger C, Rabl U, Pezawas L, Kasper S (2011) The genetic blueprint of major depressive disorder: contributions of imaging genetics studies. World J Biol Psychiatry 12:474–488PubMedCrossRef
4.
Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29:417–426PubMed
5.
Kanellopoulos D, Gunning FM, Morimoto SS, Hoptman MJ, Murphy CF, Kelly RE et al (2011) Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 19:13–22PubMedCrossRef
6.
Gonul AS, Kitis O, Eker MC, Eker OD, Ozan E, Coburn K (2011) Association of the brain-derived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biol Psychiatry 12:110–118PubMedCrossRef
7.
Eker C, Kitis O, Taneli F, Eker OD, Ozan E, Yucel K et al (2010) Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients. Eur Arch Psychiatry Clin Neurosci 260:527–533PubMedCrossRef
8.
Blugeot A, Rivat C, Bouvier E, Molet J, Mouchard A, Zeau B et al (2011) Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. J Neurosci 31:12889–12899PubMedCrossRef
9.
Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H (2012) Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 39(1):112–119
10.
Wong ML, Dong C, Andreev V, Rcos-Burgos M, Licinio J (2012) Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Mol Psychiatry 17:624–633PubMedCrossRef
11.
Kurita M, Nishino S, Kato M, Numata Y, Sato T (2012) Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS ONE 7:e39212PubMedCrossRef
12.
Dreimuller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C et al (2012) Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology 62:264–269PubMedCrossRef
13.
Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH et al. (2011) Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. Mol Psychiatry
14.
Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS (2006) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118:176–182PubMedCrossRef
15.
Gratacos M, Soria V, Urretavizcaya M, Gonzalez JR, Crespo JM, Bayes M et al (2008) A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J 8:101–112PubMedCrossRef
16.
Licinio J, Dong C, Wong ML (2009) Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66:488–497PubMedCrossRef
17.
Tsai SJ, Hong CJ, Liou YJ (2008) Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. Pharmacogenomics 9:1353–1358PubMedCrossRef
18.
Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473–500PubMedCrossRef
19.
Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y et al (2011) Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26:1–10PubMedCrossRef
20.
Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P et al (2010) Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 13:93–101PubMedCrossRef
21.
Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmuller K et al (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 20:346–355PubMedCrossRef
22.
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296PubMedCrossRef
23.
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M et al (2007) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104PubMedCrossRef
24.
Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ (2002) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43PubMedCrossRef
25.
American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157(4 Suppl):1–45
26.
Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN et al (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165:342–351PubMedCrossRef
27.
28.
Purcell S, Cherny SS, Sham PC (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149–150PubMedCrossRef
29.
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
30.
Benjamini Y, Hochberg Y (2011) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 57:289–300
31.
32.
Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ et al (2008) Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 147B:814–821PubMedCrossRef
33.
Verhagen M (2010) van der MA, van Deurzen PA, Janzing JG, rias-Vasquez A, Buitelaar JK et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15:260–271PubMedCrossRef
34.
Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N et al (2011) DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS ONE 6:e23881PubMedCrossRef
35.
Gatt JM, Kuan SA, Dobson-Stone C, Paul RH, Joffe RT, Kemp AH et al (2008) Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol Psychol 79:275–284PubMedCrossRef
36.
Gatt JM, Nemeroff CB, Schofield PR, Paul RH, Clark CR, Gordon E et al (2010) Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biol Psychiatry 68:818–824PubMedCrossRef
37.
Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR et al (2009) Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 14:681–695PubMedCrossRef
38.
Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS et al (2008) Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 13:709–716PubMedCrossRef
39.
Czira ME, Wersching H, Baune BT, Berger K (2011) Brain-derived neurotrophic factor gene polymorphisms, neurotransmitter levels, and depressive symptoms in an elderly population. Age. doi:10.​1007/​s11357-011-9313-6
40.
Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF (2010) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20:535–544PubMedCrossRef
41.
Juckel G, Schumacher C, Giegling I, Assion HJ, Mavrogiorgou P, Pogarell O et al (2010) Serotonergic functioning as measured by the loudness dependence of auditory evoked potentials is related to a haplotype in the brain-derived neurotrophic factor (BDNF) gene. J Psychiatr Res 44:541–546PubMedCrossRef
42.
Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C et al (2008) 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett 437:130–134PubMedCrossRef
43.
Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A et al (2011) Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord 132:112–120PubMedCrossRef
Metadaten
Titel
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression
verfasst von
Richard Musil
Peter Zill
Florian Seemüller
Brigitta Bondy
Michael Obermeier
Ilja Spellmann
Wolfram Bender
Mazda Adli
Isabella Heuser
Joachim Zeiler
Wolfgang Gaebel
Wolfgang Maier
Marcella Rietschel
Dan Rujescu
Rebecca Schennach
Hans-Jürgen Möller
Michael Riedel
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 5/2013
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-012-0364-1

Weitere Artikel der Ausgabe 5/2013

European Archives of Psychiatry and Clinical Neuroscience 5/2013 Zur Ausgabe

Original Paper

Twin-based study of the complex interplay between childhood maltreatment, socioeconomic status and adult memory

Short Communication

Trends in suicidality amid the economic crisis in Greece

Original Paper

Factors predicting the long-term illness course in a cohort of depressed inpatients

Editorial

The glutamate system as a therapeutic target and impact of genes on suicidality

Original Paper

MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls

Invited Review

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise